LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ Unique mechanism of action with potential to ...
Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...
This valuable study employs transition-metal FRET (tmFRET) and time-correlated single-photon counting to investigate allosteric conformational changes in both isolated cyclic nucleotide-binding ...
Preclinical data shows TERN-701's superior potency against CML resistance mutations; early clinical trial results indicate promising patient responses. Terns Pharmaceuticals announced promising ...
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from ...
Domain Therapeutics (“Domain” or “the Company”) today announces that latest preclinical data on DT-9045, a novel protease-activated receptor 2 (PAR2) Negative Allosteric Modulator candidate, will be ...
The invention in this patent application relates to 1-aminophthalazine derivatives represented generally by formula 1. These compounds are inhibitors of the interaction of the catalytic site of SOS1 ...
Scott Vengel is a writer and hobbyist based in Pennsylvania. From education to video games, he has written in a variety of different fields. He has had a passion for games since his childhood with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback